Sign in →

Test Code PARVG Parvovirus B19 Antibodies, IgG, Serum


Specimen Required


Only orderable as part of a profile. For more information see PARVS / Parvovirus B19 Antibodies, IgG and IgM, Serum.

 

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL


Secondary ID

48320

Useful For

Serologic detection of recent or past parvovirus B19 infection using IgG antibodies

 

This test is not useful as a screening procedure for the general population

Method Name

Only orderable as part of a profile. For more information see PARVS / Parvovirus B19 Antibodies, IgG and IgM, Serum.

 

Enzyme Immunoassay (EIA)

Reporting Name

Parvovirus B19 Ab, IgG, S

Specimen Type

Serum

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  14 days

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject
Other Heat-inactivated specimen

Clinical Information

Parvovirus B19 is the causative agent of fifth disease (ie, erythema infectiosum, slapped cheek syndrome), which usually produces a mild illness characterized by an intensive erythematous maculopapular facial rash. Most outbreaks of parvovirus infection are acquired by direct contact with respiratory secretions and primarily occur in the spring. Close contact between individuals is responsible for infection in schools, day care centers, and hospitals. The virus has also been associated with fetal damage (hydrops fetalis), aplastic crisis, and arthralgia. Infection during pregnancy presents the risk of transmission to the fetus that may cause intrauterine death. The rate of fetal death following maternal infection ranges between 1% and 9%.

 

Parvovirus B19 preferentially replicates in erythroid progenitor cells.(1) Infection with parvovirus B19 occurs early in life, and the virus is transmitted by respiratory secretion and occasionally by blood products. The prevalence of parvovirus B19 IgG antibodies increases with age. The age-specific prevalence of antibodies to parvovirus is 2% to 9% of children under 5 years, 15% to 35% in children 5 to 18 years of age, and 30% to 60% in adults (19 years or older).

 

Most acute infections with parvovirus B19 are diagnosed in the laboratory by serologically detecting IgG and IgM class antibodies to the virus using an enzyme-linked immunosorbent assay testing.

Reference Values

Only orderable as part of a profile. For more information see PARVS / Parvovirus B19 Antibodies, IgG and IgM, Serum.

 

Negative

Interpretation

Parvovirus B19 IgM

Parvovirus B19 IgG

Interpretation

Negative

Negative

No antibody to parvovirus B19 detected. Acute infection cannot be ruled out as antibody levels may be below the limit of detection. If clinically indicated, a second serum should be submitted in 14 to 21 days.

Negative

Positive

Results suggest past infection.

Equivocal

Positive or negative

Recommend follow-up testing in 10 to 14 days if clinically indicated.

Positive

Positive, negative or equivocal

Results suggest recent infection and should be interpreted in the context of clinical presentation.

 

The presence of IgM class antibodies suggests recent infection. The presence of IgG antibodies only is indicative of past exposure.

 

Both IgG and IgM may be present at or soon after onset of illness and reach peak titers within 30 days. Because IgG antibody may persist for years, diagnosis of acute infection is made by the detection of IgM antibodies.

Day(s) and Time(s) Performed

Monday through Friday; 11 a.m.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

86747

LOINC Code Information

Test ID Test Order Name Order LOINC Value
PARVG Parvovirus B19 Ab, IgG, S 29660-8

 

Result ID Test Result Name Result LOINC Value
PARVG Parvovirus B19 Ab, IgG, S 29660-8

Clinical Reference

1. Brown KE, Young NS: Parvovirus B19 in human disease. Ann Rev Med 1997;48:59-67

2. Markenson GR, Yancey MK: Parvovirus B19 infections in pregnancy. Semin Perinatol 1998;22(4):309-317

3. Summers J, Jones SE, Anderson MJ: Characterization of the genome of the agent of erythrocyte aplasia permits its classification as a human parvovirus. J Gen Virol 1983;64;(Pt 11):2527-2532

4. Qui J, Soderlund-Venermo M, Young NS. Human Paravoviruses. Clin Microbiol Rev. 2017 Jan;30(1):43-113. doi: 10.1128/CMR.00040-16